MaxCyte Reports Strong Third Quarter Revenue and Raises Full Year Guidance

ROCKVILLE, Md., Oct. 14, 2026 /CourierPR/ -- MaxCyte, a leading cell-engineering company, reported preliminary third-quarter 2026 financial results that showed a 26% increase in core business revenue compared to the same period in 2025. The company's total third-quarter revenue came to approximately $8.1 million, reflecting strong performance in its core business operations. In addition to the core business revenue, MaxCyte also reported strategic Platform License (SPL) Program-related revenue of more than $1 million, including a milestone revenue of $1 million received in the third quarter of 2026. The company noted that it will report royalty revenue with its full financial results on November 10, 2026.

For the full year 2026, MaxCyte raised its revenue guidance to approximately $34 million, up from the prior guidance of $30 million to $32 million. This new guidance includes core business revenue of approximately $28 million, compared to prior guidance of $25 million to $27 million. SPL Program-related revenue is expected to be approximately $6 million for the year, compared to prior guidance of approximately $5 million. SPL Program-related revenue guidance includes both revenue of approximately $4 million from milestone payments and approximately $2 million from commercial royalties.

He attributed the strong performance to accelerated instrument purchasing from a large customer, which was originally anticipated to occur in the fourth quarter. Masoud also highlighted the company's progress in its SPL Program, noting that MaxCyte is now supporting more late-stage clinical programs than ever before, with two pivotal trials that have the potential for approval as early as next year.

MaxCyte will host its third-quarter 2026 earnings conference call on November 10, 2026, at 4:30 p.m. Eastern Time. Investors are required to register online to participate. A live and archived webcast of the event will be available on the company's website at investors.maxcyte.com/events.

The company's full year 2026 revenue guidance reflects an increase of approximately 15% year-over-year growth in the second half of 2026. This growth is driven by the company's core business and its SPL Program, which is expanding its support for late-stage clinical programs. MaxCyte remains focused on executing on its strategic priorities, strengthening its position as a leading enabling technology partner in cell and gene therapy, and building a foundation for sustainable long-term growth.

The release also notes that MaxCyte's forward-looking statements are subject to risks and uncertainties, including those described in Item 1A under the heading "Risk Factors" and elsewhere in the company's report on Form 10-K for the year ended December 31, 2025. These documents are available through the Investor Menu, Financials section, under "SEC Filings" on the Investors page of the company's website at investors.maxcyte.com.